该研究检查了3D培养环境中结肠癌干细胞(CCSCs)凋亡的诱导,采用创新的冷大气等离子体(CAP)传输方法,称为两阶段转移冷大气等离子体(TS-TCAP)。TS-TCAP是一种部分或完全电离的非热气体混合物,包括光子,带电和中性粒子,和自由基,在癌症治疗等生物医学应用中获得了广泛的关注。TS-TCAP通过连续的,两步运输过程,促进活性氧和氮物质(RONS)的有效输送。TS-TCAP治疗影响CCSCs的关键细胞因子,包括IL-6和IL-8的分泌和表达水平,凋亡细胞计数,和BAX的表达,BCL-2和KI-67蛋白,使用qrt-ELISA进行评估,膜联蛋白V,和qrt-PCR程序,分别。用TS-TCAP治疗CCSCs的结果显示凋亡细胞数量显着增加(P<0.0001),分泌减少,IL-6和IL-8的基因表达(P<0.0001),伴随着BCL-2和BAX基因表达的有利改变(P<0.0001)。此外,观察到KI-67表达显着下降,与CCSCs增殖减少相关(P<0.0001)。同样,这项研究强调了TS-TCAP的抗癌潜力,展示其在降低CCSCs存活率方面的功效。然而,进一步的临床前和临床试验是必要的,以评估CAP的疗效,安全,以及与其他疗法的潜在协同作用。总的来说,TS-TCAP为CCSC治疗提供了一种有希望的替代方案,有待进一步调查和完善。
The study examines the induction of apoptosis in colon cancer stem cells (CCSCs) within a 3D culture setting, employing an innovative cold atmospheric plasma (CAP) transmission method known as two-stage transferred cold atmospheric plasma (TS-TCAP). TS-TCAP is a partially or fully ionized non-thermal gaseous mixture that comprises photons, charged and neutral particles, and free radicals, which has gained traction in biomedical applications such as cancer therapy. TS-TCAP impacts CCSCs via a continuous, two-step transport process, facilitating the efficient delivery of reactive oxygen and nitrogen species (RONS). The key cellular factors of CCSCs impacted by TS-TCAP treatment, encompassing the secretion and expression levels of IL-6 and IL-8, apoptotic cell count, and expression of BAX, BCL-2, and KI-67 proteins, were evaluated using qrt-ELISA, Annexin V, and qrt-PCR procedures, respectively. The outcomes of CCSCs treatment with TS-TCAP reveal a notable rise in the number of apoptotic cells (P<0.0001), diminished secretion, and gene expression of IL-6 and IL-8 (P<0.0001), accompanied by favorable alterations in BCL-2 and BAX gene expression (P<0.0001). Additionally, a notable decrease in KI-67 expression was observed, correlating with a reduction in CCSCs proliferation (P<0.0001). As well, this study underscores the anti-cancer potential of TS-TCAP, showcasing its efficacy in reducing CCSCs survival rates. However, further pre-clinical and clinical trials are necessary to evaluate CAP\'s efficacy, safety, and potential synergistic effects with other therapies thoroughly. Overall, TS-TCAP presents a promising alternative for CCSCs treatment, pending further investigation and refinement.